# A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Source: https://onco.cc/trials/nct06745323/  
OnCo record `nct06745323` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.

## Summary

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC is a phase 2 interventional study registered as NCT06745323 by Amgen, with 252 participants enrolled, started 2025-02-26 and due to reach its primary completion in 2029-05-10. Interventions recorded: Tarlatamab. Conditions listed: Small Cell Lung Cancer (SCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06745323
- Phase: 2
- Setting: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)
- Sponsor: Amgen
- Enrolled: 252

## Sources

- ClinicalTrials.gov NCT06745323: https://clinicaltrials.gov/study/NCT06745323

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06745323.json